Syros Pharmaceuticals (SYRS) Stock Chart & Stock Price History $0.02 +0.02 (+1,143.75%) As of 03:18 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Syros Pharmaceuticals Stock Price Performance The Syros Pharmaceuticals (SYRS) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 98.77%, with a year-to-date return of -91.34%. In the past month, the stock has decreased 0.50%, reflecting recent market activity. As of the latest close, Syros Pharmaceuticals traded at $0.00 with a market cap of $43 thousand and volume of 1,156 shares. Five years ago, the stock traded at a split-adjusted price of $144.70, representing a 99.99% decrease over that period. At the time, it had a market cap of $636.09 million and a volume of 278,400 shares. Receive SYRS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1,143.75%1 Month Performance-0.50%3 Month Performance-31.62%Year-To-Date Performance-91.34%1 Year Performance-98.77%5 Year Performance-99.99% SYRS Stock Chart for Friday, August, 22, 2025 SYRS Chart by TradingView Syros Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/21/2025$0.00$0.00-33.33%$0.00$0.001,156 shs$43,000.0008/20/2025$0.01$0.00-60.66%$0.00$0.0021,936 shs$64,000.0008/19/2025$0.00$0.01+281.25%$0.01$0.00153,228 shs$164,000.0008/18/2025$0.00$0.00$0.00$0.007,927 shs$43,000.0008/15/2025$0.00$0.00-51.52%$0.00$0.006,328 shs$43,000.0008/14/2025$0.00$0.00+200.00%$0.00$0.0057,140 shs$89,000.0008/13/2025$0.00$0.00$0.00$0.007,649 shs$30,000.0008/12/2025$0.00$0.00$0.01$0.0023,168 shs$30,000.0008/11/2025$0.00$0.00$0.00$0.009,812 shs$30,000.0008/08/2025$0.00$0.00$0.00$0.0013,727 shs$30,000.00 Get the Latest News and Ratings for SYRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 08/07/2025$0.00$0.00-26.67%$0.00$0.0029,553 shs$30,000.0008/06/2025$0.00$0.00+36.36%$0.00$0.007,889 shs$40,000.0008/05/2025$0.00$0.00$0.00$0.008,001 shs$30,000.0008/04/2025$0.00$0.00-31.25%$0.00$0.002,122 shs$30,000.0008/01/2025$0.00$0.00+33.33%$0.00$0.006,723 shs$43,000.0007/31/2025$0.00$0.00$0.00$0.0018,930 shs$32,000.0007/30/2025$0.00$0.00+9.09%$0.01$0.00138,394 shs$32,000.0007/29/2025$0.01$0.00-89.00%$0.01$0.008,568 shs$30,000.0007/28/2025$0.01$0.01-0.99%$0.03$0.0030,001 shs$268,000.0007/25/2025$0.02$0.01-49.50%$0.02$0.0041,366 shs$271,000.0007/24/2025$0.02$0.02+2.56%$0.02$0.004,651 shs$537,000.0007/23/2025$0.02$0.02-2.50%$0.02$0.0096,447 shs$523,000.0007/22/2025$0.00$0.02+471.43%$0.02$0.0013,409 shs$537,000.0007/21/2025$0.01$0.00-65.00%$0.03$0.0029,630 shs$94,000.00 Related Companies NCNA Stock Price Chart NAVB Stock Price Chart SMFL Stock Price Chart VRPX Stock Price Chart SCPS Stock Price Chart VAXX Stock Price Chart EVLO Stock Price Chart CMRA Stock Price Chart GNCAQ Stock Price Chart GNCA Stock Price Chart Receive SYRS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:SYRS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access